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rrest of circulating tumor cells in distant organs is
required for hematogenous metastasis, but the tumor
cell surface molecules responsible have not been
identiﬁed. Here, we show that the tumor cell 
 
 
 
3
 
 
 
1
 
 integrin
makes an important contribution to arrest in the lung and
to early colony formation. These analyses indicated that
pulmonary arrest does not occur merely due to size restric-
tion, and raised the question of how the tumor cell 
 
 
 
3
 
 
 
1
A
 
integrin contacts its best-deﬁned ligand, laminin (LN)-5, a
basement membrane (BM) component. Further analyses
revealed that LN-5 is available to the tumor cell in preexist-
ing patches of exposed BM in the pulmonary vasculature.
The early arrest of tumor cells in the pulmonary vasculature
through interaction of 
 
 
 
3
 
 
 
1
 
 integrin with LN-5 in exposed
BM provides both a molecular and a structural basis for
cell arrest during pulmonary metastasis.
 
Introduction
 
The lung is a frequent site for metastasis of many different
tumor types. Tumor cells enter the circulation from the
primary tumor and then colonize distant organs. The inter-
actions between the tumor cells and the vessels that allow
the initial arrest of the tumor cell in the lung are poorly
characterized, although in individual cases contributing
molecules have been identified (Abdel-Ghany et al., 2001;
Abdel-Ghany et al., 2003). Recently, we developed methods
that allow the observation of the early events in metastasis
after entry of the cells into the pulmonary circulation (Al-
Mehdi et al., 2000). Fluorescent tumor cells were introduced
i.v. into mice or rats, and their lungs were isolated and
maintained and observed under physiological conditions.
Using these methods, we showed that intravascular prolif-
eration rather than early extravasation characterized the ini-
tial events in metastatic colony formation. Here, we have
adapted these methods to study the initial arrest of tumor
cells in the pulmonary vasculature and investigate the role of
integrins in this process.
It has long been supposed that integrins play an important
role in metastasis. This supposition is based in part on the
role of integrins in motility, and in part on data showing
that agents that interrupt integrin–ligand interaction also
inhibit metastasis. For example, peptides containing the
motif RGD (Arg-Gly-Asp) that compete for binding of
integrins to fibronectin, or peptides that block binding of
integrins to laminin (LN) can inhibit metastasis when coin-
jected with tumor cells (Humphries et al., 1986; Saiki et al.,
1989; Yamamura et al., 1993). Antibodies directed against
surface integrins that affect LN binding also reduced lung
metastasis (Vollmers et al., 1984). Each integrin is a het-
erodimer composed of both an 
 
  
 
and a 
 
 
 
 subunit. The
ligand-binding domain of the integrin heterodimer is a
globular region that requires both subunits to engage the
ligand. Thus, antibodies specific for either the 
 
  
 
or the 
 
 
 
chain can be blocking. Integrins bind to components of
ECM such as collagens, fibronectin, and LNs, and can medi-
ate adhesion, spreading, or migration on these substrates
(Schwartz, 2001; van der Flier and Sonnenberg, 2001).
Using an attachment assay based on the observation of
fluorescent tumor cells in isolated lungs, we have evaluated
the involvement of integrins in the arrest of tumor cells in
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the pulmonary circulation. This report shows for the first
time that the 
 
 
 
3
 
 
 
1
 
 integrin is an important (but not exclu-
sive) component in that process. The importance of 
 
 
 
3
 
 
 
1
 
 in-
tegrin in pulmonary vascular attachment by tumor cells
raised the question of access to its ligands. LN-5, -8, -10, and
-11 are ligands for the 
 
 
 
3
 
 
 
1
 
 integrin (Nissinen et al., 1997;
Fukushima et al., 1998; Kikkawa et al., 2000; Fujiwara et al.,
2001). Each is mainly found in ECM with LN-8/9 and LN-
10/11 also present in the stroma of the bone marrow (Siler et
al., 2000). How ECM or basement membrane (BM) compo-
nents could be exposed to tumor cells in pulmonary vessels
was not immediately apparent. Unexpectedly, examination
of vessels at the sites of tumor cell attachment revealed ex-
posed BM, enabling the binding of 
 
 
 
3
 
 
 
1
 
 integrin.
 
Results
 
Assay for tumor cell arrest in the pulmonary vasculature
 
To assess the arrest of tumor cells in the lung, we injected
different numbers of fluorescent metastatic HT1080 cells
into the renal vein of rats. Immediately after the injection,
the isolated, ventilated, and perfused lungs were examined.
Fluorescent tumor cells were counted in 60 consecutive
nonoverlapping images under low power (10
 
 
 
). The curve
of arrested versus injected cells was effectively linear over a
range up to 2 
 
 
 
 10
 
6
 
 cells. Therefore, injection of cell num-
bers within the linear range was used in the subsequent ex-
periments to measure pulmonary arrest (Fig. 1 a)
 
Effects of integrins on pulmonary attachment in vivo
 
HT1080 cells are known to express 
 
 
 
1
 
, 
 
 
 
3
 
, 
 
 
 
4
 
, 
 
 
 
5
 
, and 
 
 
 
8
 
,
and 
 
 
 
1
 
, 
 
 
 
2
 
, 
 
 
 
3
 
, 
 
 
 
4
 
, 
 
 
 
5
 
, 
 
 
 
6
 
, and 
 
 
 
v
 
 integrin subunits (Peter-
mann et al., 1993). Before i.v. infusion, HT1080-GFP cells
were incubated with blocking antibodies to the 
 
 
 
1
 
, 
 
 
 
3
 
, or 
 
 
 
4
 
integrin subunits or to the 
 
 
 
v
 
 
 
5
 
 integrin. Because blocking
antibody to 
 
 
 
8
 
 integrin is not available, the effect of this inte-
grin was evaluated with the blocking antibody to 
 
 
 
v
 
, the ex-
clusive heterodimeric partner for the 
 
 
 
8
 
 integrin subunit
(Nishimura et al., 1998). Of the anti-
 
 
 
 subunit antibodies
tested, only earlier treatment with anti-
 
 
 
1
 
 blocking antibody
resulted in a significant reduction in cell attachment (Fig. 1
b). Treatment of HT1080-GFP cells with a nonblocking an-
tibody to 
 
 
 
1
 
 integrin did not alter pulmonary arrest, nor did
infusion of the blocking antibody into the lung before infu-
sion of the tumor cells (Fig. 1, c and d). These results demon-
strated that integrins including the 
 
 
 
1
 
 subunit were involved
in the arrest of HT1080 in the pulmonary vasculature.
HT1080-GFP cells were incubated with blocking anti-
bodies to the 
 
 
 
1
 
, 
 
 
 
2
 
, 
 
 
 
3
 
, 
 
 
 
4
 
, 
 
 
 
5
 
, 
 
 
 
6
 
, or 
 
 
 
v
 
 integrin subunits.
As shown in Table I, blocking antibodies against the 
 
 
 
1
 
, 
 
 
 
5
 
,
 
 
 
6,
 
 or 
 
 
 
v
 
 integrin subunits did not affect pulmonary attach-
ment. Anti-
 
 
 
3
 
 integrin subunit antibody had the greatest ef-
fect with 34% inhibition, whereas slight reductions of 15
and 16% were seen after the treatments with anti-
 
 
 
2
 
 and 
 
 
 
4
 
integrin subunits, respectively. The effect of blocking the 
 
 
 
2
 
integrin subunit was statistically significant; the effect on the
 
 
 
4
 
 integrin subunit was not. Combining these three anti-
bodies increased the inhibition, but was not entirely additive
(unpublished data). Blocking antibodies to 
 
 
 
3
 
 (but not 
 
 
 
6
 
)
integrin subunits similarly reduced pulmonary arrest by two
metastatic breast carcinoma cell lines, MDA-MB-231 and
Figure 1. Inhibition of pulmonary arrest by anti-  integrin antibodies. HT1080-GFP cells were infused into the renal vein of rats, lungs 
were isolated, and the number of fluorescent cells in a determined area of the surface was counted as described in the Materials and methods 
section. (a) Number of HT1080-GFP cells arrested on the surface 30 min after infusion of the indicated cell number. Each point represents the 
results from three rats. Based on this curve, 3   10
5 HT1080-GFP cells were used in subsequent experiments. (b) Inhibition of pulmonary 
arrest after pretreatment of HT1080 cells with the indicated blocking antibodies.  , treated without antibody;  , treated with antibody. (c) Effect 
of infusing the anti- 1 blocking antibody before injection of untreated HT1080 cells. (d) Comparison of the effect on pulmonary arrest of anti- 1 
blocking antibody to a nonblocking anti- 1 antibody.
 
Table I. 
 
Effect of anti-
 
 
 
 integrin subunit blocking antibodies on 
pulmonary arrest
Antibody 
specificity
Control Antibody Inhibition
 
cells/mm
 
2
 
   SD cells/mm
2   SD %
 1 6.00   0.53 5.78   0.65 4
 2 7.23   0.29 6.10   0.52 15
 3 7.42   1.07 4.93   1.14 34
 4 5.95   0.64 5.02   0.66 16
 5 4.65   1.73 5.03   2.57  8
 6 5.94   1.87 6.20   1.83  5
 v 6.20   1.50 6.00   2.07 3
HT1080-GFP cells were treated with the indicated blocking antibodies as
described in the Materials and methods section. Each value is expressed as
cells/mm
2   SD. The anti- 3 subunit antibody used was P1B5. Similar
results were obtained with ASC-1 (unpublished data). The comparison of
means using t test was P   0.03 for  2 integrin subunit blocking antibody
and P   0.05 for  3. The value for  4 was P   0.15.Pulmonary arrest by metastatic tumor cells | Wang et al. 937
MDA-MB-435s (Table II). Because the  3 subunit only
forms a complete integrin molecule with the  1 subunit,
these data suggest that the  3 1 integrin plays a critical role
in the early lodgment of tumor cells in the lung.
To further evaluate this hypothesis, the effect of genetic
elimination of either the  3 or the  1 subunit was tested in
pulmonary attachment. The  1 integrin subunit in ESb cells
has been eliminated through homologous recombination at
both alleles (Stroeken et al., 1998). The deficient ESb cells
were  40% less effective at pulmonary arrest than the par-
ent ESb cells (Fig. 2 a), similar to the result obtained using
HT1080-GFP cells treated with blocking antibodies. Resto-
ration of the  1 integrin by transfection of a  1a cDNA ex-
pression vector resulted in the recovery of pulmonary attach-
ment (Fig. 2 a). Likewise, genetic elimination of the  3
integrin subunit using immortalized keratinocytes derived
from an  3 integrin-deficient null mouse (MK 5.4.6
 / ) re-
sulted in a reduction of 53% in attachment compared with
immortalized keratinocytes from a wild-type mouse (MK
1.16
 / ; DiPersio et al., 1997, 2000). Restoration of  3 inte-
grin subunit expression by stable transfection (MK 5.4.6
 /   
 3) also restored attachment (Fig. 2 b). The role of the  3 1
integrin in cell attachment was also examined in K562
erythroleukemia cells that have only  1 and  5 integrin
(Burger et al., 1992). Expression of  3A integrin in K562
cells enhanced cell attachment by 40%, but  6A integrin
subunit expression had no effect (Fig. 2 c). These data fur-
ther support the contention that the  3 1 integrin partici-
pates in tumor cell pulmonary attachment.
Anti- 3 or anti- 1 integrin subunit antibody treatment of
HT1080-GFP cells also had an inhibitory effect on early
colony formation 1 wk after injection. The cells were ex-
posed to the indicated antibody before injection without any
subsequent exposure to the antibody, as in the experiments
shown in Fig. 1 b. This initial exposure was sufficient to re-
duce colony formation. The decrease in colony number ex-
ceeded the decrease in pulmonary attachment (Table III).
Initial pulmonary arrest using the  3 1 integrin appears to
play a critical role in subsequent colony formation.
 3 1 integrin ligands in vivo
LN-5 is the best-characterized ligand for the  3 1 integrin.
Because it is mainly a BM component in the lung, we ex-
pected that it would be covered by endothelium and not
available to circulating tumor cells in the pulmonary vessels
(Mizushima et al., 1998; Coraux et al., 2002). To search for
LN-5 in vascular channels, we infused two different fluores-
cently labeled antibodies to the  3 chain of LN (MIG-1 and
CM6) sequentially after the injection of HT1080-GFP-
vimentin cells (these mAbs react with rat, but not mouse
LN-5). The  3 chain of LN is found in LN-5, -6, and -7
(Colognato and Yurchenco, 2000; Nguyen et al., 2000b).
However, LN-5 is considered to be markedly more abundant
than the others (Adair-Kirk et al., 2003). Although MIG-1
generally gave a stronger signal than CM6, both anti-LN-5
antibodies stained small areas surrounding the arrested tu-
mor cells (Fig. 3, a and b). A similar signal was obtained af-
ter the infusion of antibody against the LN  2 chain (Fig. 3,
e and g). The LN  2 chain is unique to LN-5 confirming its
presence, but not excluding the presence of LN-6 or -7.
GFP-vimentin was used to label the cells because the signal
from cytoplasmic GFP alone overwhelmed the signal. To
test whether these patches existed before the infusion of tu-
mor cells, fluorescently labeled antibodies to either the  3
chain (MIG-1) or the  2 chain of LN were injected into na-
ive rats. Foci of antibody staining were found in lungs (Fig.
3, c, d, and f). They are infrequent, approximately only on
10–20 high power fields surveyed. Fluorescent antibodies to
irrelevant molecules, the cartilage-specific collagen II, or to
the platelet integrin  IIb failed to stain any vascular patches
(Fig. 3 h). These results have led us to suggest that exposed
BM preexists in the pulmonary vasculature.
To further test the hypothesis that LN-5 acts as a ligand
for the  3 1 integrin on tumor cells, we infused antibodies
to the  3 chain (CM6) before the injection of HT1080-GFP
tumor cells. These antibodies reduced the extent of pulmo-
Figure 2. The  3 1 integrin contributes to pulmonary arrest in rat 
lung. (a) Pulmonary attachment by ESb cells 
( / ), ESb cells without 
either  1 integrin allele 
( / ), or deficient cells reengineered to express 
 1a integrin (
 /     1A). (b) Pulmonary attachment by MK1.16 
( / ), 
MK5.4.6 
( / ) cell without either  3 integrin, or deficient cells reengi-
neered to express  3 (
 /     3). (c) Pulmonary arrest of K562 parental 
cells compared with K562 expressing  3 or  6 integrin subunits.
Table II. Effect of   integrin subunit blocking antibodies on pulmonary attachment by breast cancer cell lines
MDA-MB-231 MDA-MB-435s
Antibody Control Blocking 
antibody
Inhibition Control Blocking 
antibody
Inhibition
 3 6.38   0.67 4.74   0.42 26% 7.79   1.36 5.19   0.92 33%
 6 6.45   0.77 6.40   0.61 1% 7.25   1.28 7.22   0.88 0%
The effect of anti- 3 or anti- 6 subunit blocking antibodies on the breast carcinoma cell lines MDA-MB-231 and MDA-MB-435s was determined as described
in the Materials and methods section. Each value is expressed as cells/mm
2   SD.938 The Journal of Cell Biology | Volume 164, Number 6, 2004
nary attachment compared with the pulmonary arrest seen
when the antibodies were infused after injection of the tu-
mor cells (Fig. 3 i).
Interaction between tumor cells and vascular BM
We used EM as an alternative means to visualize tumor cell–
pulmonary vessel interactions. HT1080-GFP-vimentin cells
were labeled with ferritin before injection to allow their
identification. 38 tumor cells were identified, all within the
pulmonary vessels. Of these, nine cells showed distinct at-
tachment to the vessel wall in EM images. In each of these
cases, at the point of contact between the tumor cell and the
vessel, the vessel was missing the expected endothelial cover-
ing of the basal lamina (Fig. 4, a–c). When the tumor cells
were pretreated with a blocking anti- 1integrin subunit anti-
body, no points of contact were identified (0 out of 33 tu-
mor cells; P   0.001). Rare patches of exposed BM could be
found in the absence of tumor cells (Fig. 4 d). These obser-
vations lead to the hypothesis that the foci of exposed BM
between endothelial cells may be a prerequisite for tumor
cell vascular attachment in the lung.
Discussion
Our analyses have suggested that tumor cells arrest in the
pulmonary vasculature through interaction of their  3 1 in-
tegrin with exposed BM. We have shown that the  3 1 inte-
grin contributes to metastasis through mediation of early ad-
hesion to the vasculature using a variety of cells, HT1080,
MDA-MB-231 and -435s, ESb cells, K562 cells, and im-
mortalized keratinocytes. Interestingly, the  3 1 integrin is
commonly expressed by most tumor cells. In some reports,
higher expression of the  3 1 integrin correlated with in-
creased metastasis (Morini et al., 2000). Involvement of the
 1 integrin subunit in attachment is consistent with data
showing reduced metastasis by a lung carcinoma cell line af-
ter treatment with blocking antibodies to the  1 integrin
subunit (Takenaka et al., 2000). The  3 1 integrin associ-
ates with the urokinase receptor and with the tetraspanin
CD151, both implicated in metastasis (Scherberich et al.,
1998; Testa et al., 1999; Wei et al., 2001; Zhang et al.,
2001). In keratinocytes, secretion of matrix metalloprotein-
ase-9, a molecule known to influence metastasis, is depen-
dent on the  3 1 integrin (DiPersio et al., 2000). Our data
Table III. Inhibition of early colony formation by pre-treatment with anti-integrin subunit antibodies
Treatment Colonies/lung   SD Range
(# of colonies)
# of mice t test against 
no antibody
No antibody 2.25   1.71 0–5 12 -
Anti- 1 blocking 0 0 7 0.001
Anti- 1 nonblocking 2.43   1.72 1–6 7 -
Anti- 3 (P1B5) 0.71   0.76 0–2 7 0.016
Anti- 3 (ASC-1) 0.71   0.95 0–2 7 0.022
Anti- 6 1.86   2.27 0–5 7 -
HT1080-GFP cells were treated with the indicated antibodies for 0.5 h before injection as described in the Materials and methods section. After washing,
5   10
5 cells were injected into the tail vein of nu/nu mice. The numbers of colonies were counted after scanning the entire surface of the left lobe of the
isolated mouse lung. A two-tailed t test is shown only for those with a significant difference as compared to the no antibody control.
Figure 3. LN-5 can act as a ligand in 
the pulmonary vasculature. Immediately 
after infusion of HT1080-GFP-vimentin 
cells into rats, the labeled antibodies to 
LN-5 were infused. 10 min later, the 
lungs were isolated and perfused. Panels 
show representative images obtained 
with labeled (a) anti-LN  3 chain antibody 
(MIG-1), or (b) CM6. (c and d) Typical 
images seen after infusion of the Alexa 
Fluor
® 647–labeled MIG-1 antibody in 
naive rats. (e) An image after Alexa 
Fluor
®–labeled anti-LN  2 chain antibody 
staining. The image is a rotation of a 
three-dimensional reconstruction showing 
the direct proximity of the  2 staining to 
the cell. (f) LN  2 chain antibody staining 
in naive rats. (g) An HT1080-GFP-vimen-
tin cell in a vessel filled with tetramethyl-
rhodamine dextran. LN  2 staining is
seen in blue on the vessel wall. (h) Alexa 
Fluor
® control image. (i) Anti-LN  3 
chain antibody (CM6) was infused either 
before or after infusion of HT1080-GFP 
cells. When antibody infused before, 
cell attachment was less, P   0.019. 
Bars, 20  m.Pulmonary arrest by metastatic tumor cells | Wang et al. 939
further indicate that additional receptors are likely to be in-
volved in pulmonary attachment because partial (rather than
complete) blockade of attachment was achieved through in-
hibition of the  3 1 integrin.
The observation that antibodies to components of LN-5
stained foci in pulmonary vessels and that anti-LN  3 chain
antibodies block pulmonary arrest provided evidence for
LN-5 as a vascular ligand for the tumor cell  3 1 integrins.
A potential role for LN-6 is not addressed by these analyses.
The structural basis for this staining was shown in EM indi-
cating sporadic absence of overlying endothelial cells in
small patches in the pulmonary vessels. Menter et al. (1987)
also found EM evidence for direct contact between tumor
cells and pulmonary BM. One might expect that these ab-
sences could lead to loss of the fluid barrier. However, in the
lung fluid integrity is in fact maintained by the tight junc-
tions of the alveolar cells, not the endothelium (Schnee-
berger-Keeley and Karnovsky, 1968). One might also have
expected platelet aggregation. However, the exposure of the
surface of the basal lamina or the BM might not expose col-
lagens, or more specifically, their helical domains. In some
BMs, the collagens appear to be beneath the basal lamina
(Nguyen et al., 2000a). Consistent with this possibility,
anti-collagen IV antibody only stained poorly in our hands
(unpublished data). This would also explain why the ex-
posed BM regions do not have associated platelet aggrega-
tion. Metastasis may favor the lung because of this unique
feature of its vessels. Whether arrest in the bone marrow is
influenced by the  3 1 integrin binding with LN-8/9 or
LN-10/11 remains to be studied. Other organs may also use
different adhesion factors. For example, expression of the  5
integrin subunit enhances the arrest of tumor cells in the
kidney glomeruli, but does not affect cell attachment in the
lung or the liver (Tani et al., 2003).
The  6 4 integrin also binds to LN-5, yet anti- 6 integrin
subunit antibody failed to alter attachment in vivo in our ex-
periments. There are other situations in which the  6 4 in-
tegrin and the  3 1 integrin function differently. Antibodies
to the  3 integrin subunit blocked migration of pancreatic
carcinoma cell lines and inhibited adhesion of keratinocytes
to LN-5, whereas antibodies to the  6 subunit failed to have
these effects (Tani et al., 1997; Hintermann et al., 2001).
The signaling pathways through these two integrins are dis-
tinct in keratinocytes (Hintermann et al., 2001; Mercurio et
al., 2001b). The  6 4 integrin is critical for the formation of
hemidesmosomes, whereas the  3 1 integrin regulates adhe-
sion, spreading, and migration in association with the ECM
(Borradori and Sonnenberg, 1999). Nonetheless, the  6 4
integrin clearly plays a role in metastasis, if not a demonstra-
ble role in the early arrest of tumor cells in the lung (Mercu-
rio et al., 2001a; Jauliac et al., 2002). Metastasis to the
mouse lung is inhibited both by pretreatment of the lung
with anti- 6 integrin subunit antibody and treatment of the
tumor cells with the antibody (Ruiz et al., 1993). Further-
more,  6 integrin was shown to contribute to survival of
breast carcinoma cells as they formed metastatic colonies
(Wewer et al., 1997). The  6 1 can also bind LN-5. Some
of the actions attributed to the  6 subunit may involve this
integrin. Thus, the  6 integrin subunit may augment me-
tastasis, not through enhancing pulmonary arrest, but by fa-
cilitating survival or proliferation. Pauli’s group has shown
that the  4 integrin subunit on tumor cells can ligate to en-
dothelial-bound CLCA1, mediating a signaling cascade that
includes FAK activation (Abdel-Ghany et al., 2002). Al-
though they have postulated that this interaction initiates
vascular arrest, their data are equally comparable with a
model synthesizing our data in which the tumor cell  3 1
integrin interacts with exposed LN-5, allowing subsequent
interactions that then signal for intravascular survival and
proliferation. CLCA1 may be one of the factors that con-
tribute to pulmonary arrest in addition to the  3 1 integrin.
This model is consistent with the observation that pulmo-
nary metastasis is enhanced by endothelial damage. Both hy-
peroxia and bleomycin or other chemotherapeutic drugs in-
duce endothelial injury and lead to exposure of the BM
(Nicolson and Custead, 1985; Orr et al., 1986; Lichtner and
Nicolson, 1987). Orr et al. (1986) demonstrated that endo-
thelial damage with bleomycin promoted pulmonary me-
Figure 4. EM shows tumor cells attached to exposed BM. HT1080-
GFP-vimentin cells were exposed to ferritin before injection into 
rats. Lungs were isolated and fixed with glutaraldehyde by perfusion. 
(a) A representative image from EM with a tumor cell with internalized 
ferritin within a small vessel and two contact points seen between 
the tumor cell and the vessel wall. (b) An enlargement of a contact 
point. At the contact point, the expected overlying endothelium is 
absent, showing the tumor cell attached to the BM. (c) A tracing of 
the structures in b. (d) An incidental portion of exposed BM found in 
lung not involved by tumor.940 The Journal of Cell Biology | Volume 164, Number 6, 2004
tastasis, and most of the arrested cells were found attached to
the endothelial BM. It has been proposed that tumor cells
induce the retraction of endothelial cells, enhancing me-
tastasis (Honn et al., 1989, 1994). Our results suggest that
LN-5 is available before interaction with tumor cells, but
they do not preclude further retraction after arrest.
These analyses put forward a new model for pulmonary
metastasis in which tumor cells use the  3 1 integrin to bind
to LN-5 in exposed BM. Colony formation was decreased
more extensively than attachment by blockage of the  3 1
integrin subunits, suggesting that in addition to mediating
adhesion, the  3 1 integrin may also provide important sig-
naling for other steps required for metastasis.
Materials and methods
Cell lines and culture conditions
HT1080 cells were transfected with pEGFP-C2 (CLONTECH Laboratories,
Inc.; Al-Mehdi et al., 2000) and pEGFP-vimentin (a gift from Joe Sanger,
University of Pennsylvania, Philadelphia, PA), and were screened for fluo-
rescence after selection with 800  g/ml geneticin. ESb cells (a sponta-
neous high metastatic variant of Eb that is a chemically induced T cell
lymphoma of DBA/2 mice) and derivatives were gifts from E. Roos
(Netherlands Cancer Institute, Amsterdam, Netherlands) and were cul-
tured as described previously (Stroeken et al., 1998). MDA-MB-231 and
MDA-MB-435s cell lines were obtained from the American Type Culture
Collection and were grown as recommended. Immortalized mouse kerati-
nocyte cell lines (MK cell lines) from wild-type or  3-deficient mice were
isolated using a temperature-sensitive mutant of SV-40 large T antigen and
cultured as described previously (DiPersio et al., 2000). K562 and K562
expressing the  3 or  6 integrin subunits generated by Weitzman et al.
(1997) were gifts from M. Zutter (Vanderbilt University, Nashville, TN) and
A. Sonnenberg (Netherlands Cancer Institute).
Monoclonal antibodies
All antibodies used for the tumor cell attachment in vivo assay were pur-
chased from CHEMICON International. The blocking anti-integrin antibod-
ies were as follows: anti- 1 from clone 6S6 (Shang et al., 2001); anti- 3,
clone B3A; anti- 4[CD104], clone ASC-3; anti- v 5, clone P1F6; anti- v,
clone AV1; anti- 1 I domain, clone FB12; anti- 2, clone P1E6; anti- 3, clone
P1B5 and anti- 3, clone ASC (Wayner et al., 1988; Wagner et al., 1991);
anti- 4, clone P1H4; anti- 5, clone P1D6; and anti- 6, clone NK1-GoH3.
The anti- 1 integrin nonblocking stimulating antibody is clone 21C8.
MIG-1 and CM6 are mouse mAbs raised against different domains of
the  3 chain of LN-5. Both antibodies react with rat, but not murine LN-5
(Plopper et al., 1998; Shang et al., 2001). Anti-LN  2 chain antibody was
purchased from CHEMICON International. Antibodies against LNs, or col-
lagen II, were freshly labeled with Zenon mouse IgG labeling kits; Alexa
Fluor
® 647 (Molecular Probes, Inc.) in a ratio of 10  g antibody:50  l la-
beling reagent:50  l blocking reagent.
Treatment of cells with antibodies
Cells were harvested, washed with serum-free medium, and resuspended in
the same medium containing 0.1% BSA. The suspensions were incubated
with antibodies (10  g/ml) at 4 C for 30 min on a rotator, followed by dilu-
tion with equal volume of the same medium. Although some reports have
indicated that treatment with anti- 3 integrin subunit antibody can lead to
aggregation of keratinocytes (Nguyen et al., 2001), to ensure that aggrega-
tion was not occurring in our experiments, we verified that the cells were in
single-cell suspension before injection. As additional confirmation, we
point out that we did not see cells in aggregates in the lung after injection.
Intravital attachment test
Tumor cells were labeled by either stable GFP expression (HT1080-GFP
and HT1080-GFP-vimentin) or vital fluorescence dyes. ESb cells and deriv-
atives were incubated in 100  M CellTracker™ Green CMFDA (Molecular
Probes, Inc.) in a medium containing 10% FBS at 37 C for 30 min. K562
cells, MK cells, and MDA-MB-231 or -435s cells were labeled with the vital
dye MitoTracker
® Red CMXRos (200 nM; Molecular Probes, Inc.) by 5 min
exposure in culture medium. Experiments using CMFDA or MitoTracker
®
Red on HT1080-GFP cells gave the same results as monitoring GFP. Male
rats ( 250 g; Sprague-Dawley) were injected into the renal vein with 3  
10
5 cells unless otherwise indicated. For colony assays, female mice (CD-1
nude; Charles River Laboratories) received 5   10
5 cells in the lateral tail
vein. 30 min after injection for the attachment assays or 1 wk after injection
for the colony assays, the lungs were ventilated, perfused, and isolated un-
der physiological pressures as described previously (Al-Mehdi et al., 1998,
2000). Fluorescent tumor cells were observed in the isolated lungs using an
inverted fluorescent research microscope (model DMIRB; Leica), and im-
ages were recorded with a camera (Orca; Hamamatsu Photonics) with
OpenLab software (Improvision). The quantitative assays were based on
counting cells in 60 consecutive and nonoverlapping fields with a 10 /1 
lens (1.1 mm
2 field/picture). Rats and mice were matched by weight, and
each antibody was tested in matched pairs of animals. The results were ob-
tained from at least three independent experiments in all cases.
Confocal scanning laser microscopy
5 min after injection of HT1080-GFP-vimentin cells (10
6) into the left renal
vein, antibody–Alexa Fluor
® complexes were introduced through the infe-
rior vena cava. Lungs were isolated as described above. The pulmonary
vasculature was labeled by perfusion with tetramethylrhodamine dextran
(Molecular Probes, Inc.). The images were captured using a laser scanning
system (Radiance 2000; Bio-Rad Laboratories) and a microscope (Eclipse
TE300; Nikon). The 2-line Argon/kryotin laser (wavelength 488 nm/568 nm)
and the red laser diode (wavelength 638 nm) were used for observation.
Transmission EM observation
HT1080-GFP-vimentin cells were labeled with the electron-dense marker
ferritin at 4 C for 10 min. 5 or 30 min after i.v. injection (2   10
6 cells) into
rats, the lung was dissected as described above. Afterwards, the lung was
washed with PBS, followed by perfusion with 5% glutaraldehyde. Samples
were collected from the upper region of the left lung and fixed in 2.5%
glutaraldehyde at 4 C. The images were photographed with a transmission
electron microscope, 80 kV (JEM-1010; JEOL USA, Inc.)
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